ACT Therapeutics

ACT Therapeutics' ACT Platform is an advanced CAR-T technology with a next-generation structure surpassing second-generation CAR-T cell therapies. It targets existing blood cancers while overcoming the immunosuppressive microenvironment of solid tumors and activating surrounding immune cells. Various studies have obtained animal experimental data on the efficacy and safety of the ACT platform, confirming its therapeutic properties in the immunosuppressive microenvironment of solid cancers. It also compensates for the shortcomings of existing second-generation CAR-T, making it a competitive technology for solid tumors.